

*AMENDMENTS TO THE CLAIMS*

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. – 14. Canceled.

15. (New) A process for providing a human with a therapeutic protein comprising: introducing autologous human cells into a human, said autologous human cells having been treated *in vitro* to insert therein a DNA segment encoding a therapeutic protein, said autologous human cells expressing *in vivo* in said human a therapeutically effective amount of said therapeutic protein, wherein said therapeutic protein is an interleukin, wherein the autologous human cells are T lymphocytes.

16. – 19. Canceled.

20. (New) The process of claim 15, wherein said cells are tumor infiltrating lymphocytes (TIL).

21. - 24. Canceled.

25. (New) The process of claim 15 or 20, wherein said DNA segment has been inserted into said cells *in vitro* by a viral vector.

26. (New) The process of claim 25, wherein said viral vector is a retroviral vector.

27. – 29. Canceled.

30. (New) The process of claim 15, wherein the interleukin is selected from the group consisting of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, and IL-12.

31. (New) The process of claim 30, wherein the interleukin is IL-2.

32. – 33.      Canceled.